IQVIA Holdings Inc. (NYSE:IQV) Given Average Rating of “Moderate Buy” by Analysts

IQVIA Holdings Inc. (NYSE:IQV) has been assigned a consensus rating of “Moderate Buy” from the twenty analysts that are covering the firm, MarketBeat.com reports. Three research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month price target among analysts that have covered the stock in the last year is $251.22.

A number of equities research analysts have recently weighed in on IQV shares. StockNews.com lowered shares of IQVIA from a “buy” rating to a “hold” rating in a report on Thursday, November 28th. TD Cowen lowered their price target on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Deutsche Bank Aktiengesellschaft reduced their price objective on IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Truist Financial reissued a “buy” rating and issued a $263.00 target price (up previously from $261.00) on shares of IQVIA in a research note on Monday, February 10th. Finally, William Blair reaffirmed an “outperform” rating on shares of IQVIA in a research note on Wednesday, December 11th.

Insiders Place Their Bets

In other news, Director John G. Danhakl purchased 1,275 shares of the company’s stock in a transaction that occurred on Tuesday, December 3rd. The shares were bought at an average cost of $200.58 per share, for a total transaction of $255,739.50. Following the completion of the transaction, the director now directly owns 1,275 shares of the company’s stock, valued at $255,739.50. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 1.60% of the company’s stock.

Hedge Funds Weigh In On IQVIA

Several institutional investors and hedge funds have recently added to or reduced their stakes in IQV. Smith Group Asset Management LLC purchased a new stake in shares of IQVIA in the 4th quarter worth about $1,616,000. Simplify Asset Management Inc. grew its holdings in IQVIA by 67.8% in the third quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company’s stock worth $2,284,000 after purchasing an additional 3,894 shares during the period. Nordea Investment Management AB increased its stake in shares of IQVIA by 47.4% during the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock valued at $277,908,000 after purchasing an additional 452,029 shares in the last quarter. Hickory Asset Management Inc. purchased a new position in shares of IQVIA during the fourth quarter valued at approximately $941,000. Finally, Fifth Third Bancorp boosted its position in shares of IQVIA by 13.0% in the 4th quarter. Fifth Third Bancorp now owns 13,179 shares of the medical research company’s stock worth $2,590,000 after purchasing an additional 1,521 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Stock Down 0.1 %

IQV opened at $190.77 on Thursday. The business’s fifty day simple moving average is $199.40 and its 200 day simple moving average is $215.46. IQVIA has a 52 week low of $187.62 and a 52 week high of $261.73. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The stock has a market cap of $33.59 billion, a PE ratio of 25.44, a P/E/G ratio of 1.99 and a beta of 1.48.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, research analysts expect that IQVIA will post 10.84 earnings per share for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.